Hounaida Mahfoud on Hemoperitoneum in Case of Type 3 VWD
Hounaida Mahfoud, Assistant Professor at Faculty of Medicine and Pharmacy of Rabat, shared on LinkedIn:
”Delighted to share the publication of our article on a difficult case managed successfully, thanks to my mentor Pr Mohamed El Khorassani and the dedicated ICU team at Hôpital de Maternité Souissi.
Honoured to be part of this work.
Hemoperitoneum secondary to a ruptured hemorrhagic C is usually a benign and self-limiting condition, but in women with type 3 von Willebrand disease (VWD), it may evolve into a severe and potentially life-threatening event due to the inability to achieve spontaneous hemostasis.
We report a case of a 30-year-old woman with type 3 VWD who presented with acute pelvic pain and profound anemia.
Transvaginal ultrasonography and MRI demonstrated a ruptured hemorrhagic ovarian cyst associated with a large hemoperitoneum.
Despite the extent of bleeding, the patient remained hemodynamically stable and was managed conservatively.
Treatment consisted of von Willebrand factor replacement, blood transfusion, analgesia, and close clinical and radiological monitoring.
Her condition improved progressively, with normalization of hemoglobin levels, resolution of symptoms, and significant regression of the hemoperitoneum on follow-up imaging.
No surgical intervention was required. Managing ovarian cyst rupture in severe VMD is particularly challenging, as surgical intervention carries substantial hemorrhagic risk.
Conservative management, when supported by adequate hemostatic therapy, can be both safe and effective, preserving ovarian function and reducing perioperative morbidity.
This case underscores the importance of individualized, multidisciplinary care to optimize management strategies in women with severe bleeding disorders.”
Read the full article here.
Article: Conservative Management of Hemoperitoneum Due to a Ruptured Hemorrhagic Ovarian Cyst in Type 3 von Willebrand Disease
Authors: Hounaida Mahfoud, Rim Laaboudi, Mohamed Elkhorassani, Nabil Elachhab, Samir Bargach
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 15, 2026, 13:51Matías J Alet: Hospital Carlos Saporiti on the Path to Essential Stroke Center Recognition
-
Apr 15, 2026, 13:39Congratulations to Sandy Middleton for Taking the 2026 HESTA Australian Nursing and Midwifery Awards – Stroke Foundation
-
Apr 15, 2026, 13:25Wolfgang Miesbach: Platelet Variation and How Do They Move Over Time?
-
Apr 15, 2026, 12:44Marwa Elnahas: 4Ts Scoring Tool for Heparin – Induced Thrombocytopenia
-
Apr 15, 2026, 12:27Laurent Bertoletti: Joining Global Experts to Improve Thrombosis Care in Cancer for the ICTHIC 16th Edition
-
Apr 15, 2026, 12:13Francesco Antonio Veneziano: JCDD MDPI Calls for Papers on Advances in Thrombosis and Antithrombotic Therapy
-
Apr 15, 2026, 11:05Julius Kyei Baffour: Understanding Thrombophilia Testing and Patient Risk
-
Apr 15, 2026, 09:10Shall I Bleed Less with Age? Just 2 Weeks Until the Webinar – EHC
-
Apr 15, 2026, 08:51Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease